COVID-19 Convalescent Plasma

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
COVID-19 Convalescent Plasma is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 12/28/21) permitting the use of high-titer COVID-19 convalescent plasma only for patients who are immunosuppressed or receiving immunosuppressive therapy, whether hospitalized or ambulatory.
  • The FDA EUA specifies the following:
    • Only high titer plasma units are authorized for administration. COVID-19 convalescent plasma must be tested for anti-SARS-CoV-2 antibodies with 1 of 6 available kits (See Appendix A in 12/28/21 EUA)
    • The administration should be initiated with 1 unit (200 mL).
      • Additional convalescent plasma units may be administered based on the patient’s clinical response.
    • Physicians should consider using COVID-19 convalescent plasmas among patients with impaired humoral immunity.
    • Healthcare providers must make the FDA Fact Sheet for Patients and Parents/Caregivers available before use.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 12/28/21) permitting the use of high-titer COVID-19 convalescent plasma only for patients who are immunosuppressed or receiving immunosuppressive therapy, whether hospitalized or ambulatory.
  • The FDA EUA specifies the following:
    • Only high titer plasma units are authorized for administration. COVID-19 convalescent plasma must be tested for anti-SARS-CoV-2 antibodies with 1 of 6 available kits (See Appendix A in 12/28/21 EUA)
    • The administration should be initiated with 1 unit (200 mL).
      • Additional convalescent plasma units may be administered based on the patient’s clinical response.
    • Physicians should consider using COVID-19 convalescent plasmas among patients with impaired humoral immunity.
    • Healthcare providers must make the FDA Fact Sheet for Patients and Parents/Caregivers available before use.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 14, 2022